Prognostic value of minimal residual disease detected by EuroFlow next-generation flow cytometry and next-generation sequencing in patients with multiple myeloma achieving complete response and receiving lenalidomide maintenance after autotransplant: a prospective comparison study

Takeshi Yoroidaka,[1]* Hiroyuki Takamatsu,[1]* Ryota Urushihara,[2] Mitsuhiro Itagaki,[3] Satoshi Yoshihara,[4] Kota Sato,[5] Naoki Takezako,[6] Shuji Ozaki,[7] Kazuhito Suzuki,[8] Kentaro Kohno,[9] Tsuyoshi Muta,[3] Morio Matsumoto,[10] Yasushi Terasaki,[11] Takeshi Yamashita,[12] Shin-ichi Fuchida,[13] Jun Sakamoto,[14] Tadao Ishida,[5] Kenshi Suzuki,[5] Hirokazu Murakami,[15] Brian G. M. Durie[16] and Kazuyuki Shimizu[17]

[1]Department of Hematology, Faculty of Medicine, Institute of Medical, Pharmaceutical, and Health Sciences, Kanazawa University, Kanazawa, Japan; [2]Department of Hematology, Toyama Prefectural Central Hospital, Toyama, Japan; [3]Department of Hematology, Hiroshima Red Cross Hospital and Atomic-bomb Survivors Hospital, Hiroshima, Japan; [4]Department of Respiratory Medicine and Hematology, Hyogo College of Medicine, Nishinomiya, Japan; [5]Department of Hematology, Japanese Red Cross Medical Center, Tokyo, Japan; [6]Department of Hematology, Nerima Hikarigaoka Hospital, Tokyo, Japan; [7]Department of Hematology, Tokushima Prefectural Central Hospital, Tokushima, Japan; [8]Division of Clinical Oncology and Hematology, Department of Internal Medicine, The Jikei University School of Medicine, Tokyo, Japan; [9]Department of Hematology, Japan Community Healthcare Organization Kyusyu Hospital, Kitakyushu, Japan; [10]Department of Hematology, NHO Shibukawa Medical Center, Shibukawa, Japan; [11]Division of Hematology, Toyama City Hospital, Toyama, Japan; [12]Department of Hematology, Ishikawa Prefectural Central Hospital, Kanazawa, Japan; [13]Department of Hematology, Japan Community Health care Organization Kyoto Kuramaguchi Medical Center, Kyoto, Japan; [14]Bio Medical Laboratories (BML), INC., Kawagoe, Japan; [15]Faculty of Medical Technology and Clinical Engineering, Gunma University of Health and Welfare, Maebashi, Japan; [16]Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Outpatient Cancer Center, Los Angeles, CA, USA and [17]Department of Hematology, Higashi Nagoya National Hospital, Nagoya, Japan

*TYo and HT contributed equally as first authors.

Supplemental Figure 1.
Overall Survival according to MRD negativity by NGF

Supplemental Figure 1. Overall survival (OS) stratified by minimal residual disease (MRD) status by NGF (cutoff: 10^{-5} or 2×10^{-6}). OS based on MRD negativity by NGF at PRE (cutoff: 10^{-5}) (A), at POST1 (cutoff: 10^{-5}) (B) and at POST2 (cutoff: 10^{-5}) (C). OS based on sustained MRD negativity by NGF (cutoff: 10^{-5}) (D). OS based on MRD negativity by NGF at PRE (cutoff: 2×10^{-6}) (E), at POST1 (cutoff: 2×10^{-6}) (F) and at POST2 (cutoff: 2×10^{-6}) (G). (H) OS based on sustained MRD negativity by NGF (cutoff: 2×10^{-6}). NGF: next-generation flow cytometry, NGS: next-generation sequencing, ASCT: autologous stem cell transplantation.

Supplemental Figure 2
Overall Survival according to MRD negativity by NGS

Supplemental Figure 2. Overall survival (OS) stratified by minimal residual disease (MRD) status by NGS (cutoff: 10^{-5} or 10^{-6}). OS based on MRD negativity by NGS at PRE (cutoff: 10^{-5}) (A), at POST1 (cutoff: 10^{-5}) (B) and at POST2 (cutoff: 10^{-5}) (C). OS based on sustained MRD negativity by NGS (cutoff: 10^{-5}) (D). OS based on MRD negativity by NGS at PRE (cutoff: 10^{-6}) (E), at POST1 (cutoff: 10^{-6}) (F) and at POST2 (cutoff: 10^{-6}) (G). OS based on sustained MRD negativity by NGS (cutoff: 10^{-6}) (H). NGF: next-generation flow cytometry, NGS: next-generation sequencing, ASCT: autologous stem cell transplantation.

Supplemental Figure 3. Progression free survival (PFS) stratified by minimal residual disease (MRD) status and cytogenetic risks. (A) PFS stratified by cytogenetic risks. (B) PFS stratified by MRD status using NGF and cytogenetic risks at PRE. (C) PFS stratified by MRD status using NGF and cytogenetic risks at POST1. (D) PFS stratified by MRD status using NGS and cytogenetic risks at PRE. (E) PFS stratified by MRD status using NGS and cytogenetic risks at POST1. SR: standard-risk, HR: high-risk, NGF: next-generation flow cytometry, NGS: next-generation sequencing, ASCT: autologous stem cell transplantation, *: p<0.05, **: p<0.01.

Supplemental Figure 4. Correlations of minimal residual disease (MRD) levels between

PRE-bone marrow (BM) and autograft by next-generation sequencing (NGS) and

survival based on MRD levels. (A) Comparison of MRD levels between PRE-bone marrow

and autograft determined by NGS. Progression-free survival (PFS) based on MRD negativity

in autografts (cutoff: 10^{-6}) (B) and sustained MRD negativity (autograft and Pre) (cutoff: 10^{-6}) (C). Overall survival (OS) based on MRD negativity in autografts (cutoff: 10^{-6}) (D) and

sustained MRD negativity (autograft and Pre-BM) (cutoff: 10^{-6}) (E). (-): negative, (+):

positive.